Publications by authors named "Bart Frederick"

Claim this Profile
T
The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
Ivo Nnane, Bart Frederick, Zhenling Yao, Donald Raible, Cathye Shu

Br J Clin Pharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
Derrick E Akpalu, Bart Frederick, Ivo P Nnane, Zhenling Yao, Fang Shen

J Clin Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
Zhenhua Xu, Stanley J Marciniak, Bart Frederick, Lilianne Kim, Yanli Zhuang

Clin Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
Chao Xu, Chao Han, Joseph Marini, Joyce Ford, Stanley Marciniak, Bart Frederick

Clin Pharmacol Drug Dev· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
Mittie K Doyle, Mahboob U Rahman, Bart Frederick, Charles A Birbara, Dick de Vries

Rheumatology (Oxford)· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
Yaowei Zhu, Qingmin Wang, Bart Frederick, Esther Bouman-Thio, Joseph C Marini

Clin Drug Investig· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Yanli Zhuang, Zhenhua Xu, Bart Frederick, Dick E de Vries, Joyce A Ford

Clin Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Zhenhua Xu, Esther Bouman-Thio, Craig Comisar, Bart Frederick, Bart Van Hartingsveldt

Br J Clin Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
Zhenhua Xu, Qingmin Wang, Yanli Zhuang, Bart Frederick, Hong Yan

J Clin Pharmacol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Esther Bouman-Thio, Kari Franson, Bruce Miller, John Getsy, Adam Cohen, Bart Frederick

J Clin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Alice B Gottlieb, Kevin D Cooper, Thomas S McCormick, Eiko Toichi, Daniel E Everitt, Bart Frederick

Curr Med Res Opin· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Eiko Toichi, Gisela Torres, Thomas S McCormick, Timothy Chang, Mary Ann Mascelli, Bart Frederick

J Immunol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
Catharine L Kauffman, Nancy Aria, Eiko Toichi, Thomas S McCormick, Kevin D Cooper, Bart Frederick

J Invest Dermatol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.
Mirna Urquidi-Macdonald, Donald E Mager, Mary A Mascelli, Bart Frederick, Jane Freedman

Clin Pharmacol Ther· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Darrell R Abernethy, John Pezzullo, Mary A Mascelli, Bart Frederick, Neal S Kleiman

Clin Pharmacol Ther· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
Jane Freedman, Mary A Mascelli, John C Pezzullo, Elliot S Barnathan, Bart Frederick

Am Heart J· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis